Detail Drug Dependence; Cancer Medicine   Oleh:  [s.n] Jenis: Article from Bulletin/Magazine Dalam koleksi: The Economist (http://search.proquest.com/) vol. 407 no. 8831 (Apr. 2013), page 77. Topik: Cancer; Cancer Therapies; Pharmaceutical Sciences; Medical Research Ketersediaan Perpustakaan Pusat (Semanggi) Nomor Panggil: EE29.76 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada     Lihat Detail Induk Isi artikel Less is sometimes more. That was the message delivered this week by Meghna Das Thakur of the Novartis Institutes for Biomedical Research. If a cancer evolves resistance to the drug being used to treat it, withdrawing that drug can sometimes stop the cancer in its tracks as effectively as prescribing treatment in the first place. Oncologists have suspected this for a while. Dr Thakur has, however, proved it is true--at least in the specific case of malignant melanoma and a drug called vemurafenib. It was one of the first reasonably reliable treatments for metastised melanoma. The problem is that continual mutation within what little of the tumour remains usually throws up resistant cell lines, and so most patients see their tumours rebound between six and nine months later. Once that happens, little can be done. Or so it seemed. But Dr Thakur and her colleagues wondered if the apparently counter-intuitive approach of withdrawing treatment might have a positive effect. Opini Anda Klik untuk menuliskan opini Anda tentang koleksi ini! Kembali

Copyright © 2006, 2007 Unika Atma Jaya, all rights reserved